Lista de obras - Annette Bruchfeld - Dominio Público Uruguay

Albuminuria as a risk factor for mild cognitive impairment and dementia—what is the evidence?

artículo científico publicado en 2021

Altered Protein Composition of Subcutaneous Adipose Tissue in Chronic Kidney Disease

artículo científico publicado en 2017

Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis.

artículo científico publicado en 2016

Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials

scientific article published on 01 July 2019

Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis.

artículo científico publicado en 2007

Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.

artículo científico publicado en 2002

ERA-EDTA invests in transformation to greener health care

article

Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis

scientific article published on 15 July 2019

Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia

artículo científico publicado en 2006

Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation.

artículo científico publicado en 2009

Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement

artículo científico publicado en 2009

Erratum to Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials

scientific article published on 12 April 2019

Funding kidney research as a public health priority: challenges and opportunities

artículo científico publicado en 2020

Gamma glutamyltranspeptidase activity and viral hepatitis in dialysis population

scientific article published on 01 January 2007

Genetically distinct subsets within ANCA-associated vasculitis

scientific journal article

Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation

scientific article published on 01 September 2004

High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD).

artículo científico publicado en 2008

High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.

artículo científico publicado en 2005

High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations

artículo científico publicado en 2010

Interferon and ribavirin therapy in dialysis patients with chronic hepatitis C.

artículo científico publicado en 2001

Interferon therapy for HCV-associated glomerulonephritis: meta-analysis of controlled trials.

artículo científico publicado en 2007

Interferon/pegylated interferon and ribavirin in HCV-associated kidney disease with or without cryoglobulinemia.

artículo científico publicado en 2005

Lancet Countdown paper: what does it mean for nephrology?

scientific article published on 01 January 2019

Macrophage migration inhibitory factor (MIF) and thyroid hormone alterations in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

artículo científico publicado en 2013

Mild cognitive impairment and kidney disease: clinical aspects

artículo científico publicado en 2020

Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial

scientific article published on 05 January 2019

Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe

artículo científico publicado en 2019

Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe

Nephrology: achieving sustainability

artículo científico publicado en 2020

Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges

artículo científico publicado en 2021

Outcome and treatment of elderly patients with ANCA-associated vasculitis

artículo científico publicado en 2015

Paving the way towards gender equality: how are we faring in nephrology?

scientific article published on 01 April 2020

Pegylated interferon and ribavirin in haemodialysis patients.

artículo científico publicado en 2006

Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients.

artículo científico publicado en 2006

Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients

artículo científico publicado en 2014

Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis

artículo científico publicado en 2010

Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.

artículo científico publicado en 2011

Recommendations for the management of patients with immune-mediated kidney disease during the severe acute respiratory syndrome coronavirus 2 pandemic

scientific article published on 23 May 2020

Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis

artículo científico publicado en 2012

Renal-limited vasculitis in children: a single-center retrospective long-term follow-up analysis

scientific article published on 01 November 2013

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis

scientific article published on 24 June 2020

Rituximab for minimal change disease in adults: long-term follow-up

artículo científico publicado en 2013

Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?

scientific article published on 14 September 2020

Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients

scientific article published on 28 November 2011

Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.

artículo científico

Serum Glutaredoxin Activity as a Marker of Oxidative Stress in Chronic Kidney Disease: A Pilot Study

scientific article published on 25 September 2018

Serum retinol-binding protein concentration and its association with components of the uremic metabolic syndrome in nondiabetic patients with chronic kidney disease stage 5.

artículo científico publicado en 2008

The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council

artículo científico publicado en 2018

The council for new therapies should immediately revoke their decision on eculizumab

artículo científico publicado en 2015

The influence of hepatitis C and iron replacement therapy on plasma pentosidine levels in haemodialysis patients.

artículo científico publicado en 2004

The nephrology crystal ball: the medium-term future

artículo científico publicado en 2020

Treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia—anti-viral therapy vs rituximab

scientific article published on 05 May 2006

Whole blood cytokine attenuation by cholinergic agonists ex vivo and relationship to vagus nerve activity in rheumatoid arthritis.

artículo científico publicado en 2010

[23 physicians comments on circumcision of small boys: The Swedish Medical Association should take a more humble approach].

artículo científico publicado en 2014

[The council for new therapies position on eculizumab is unacceptable]

artículo científico publicado en 2015

Lista de obras de Annette Bruchfeld

Albuminuria as a risk factor for mild cognitive impairment and dementia—what is the evidence?

Altered Protein Composition of Subcutaneous Adipose Tissue in Chronic Kidney Disease

Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis.

Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials

Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis.

Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.

ERA-EDTA invests in transformation to greener health care

Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis

Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia

Elevated serum macrophage migration inhibitory factor (MIF) concentrations in chronic kidney disease (CKD) are associated with markers of oxidative stress and endothelial activation.

Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement

Erratum to Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials

Funding kidney research as a public health priority: challenges and opportunities

Gamma glutamyltranspeptidase activity and viral hepatitis in dialysis population

Genetically distinct subsets within ANCA-associated vasculitis

Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation

High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD).

High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.

High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations

Interferon and ribavirin therapy in dialysis patients with chronic hepatitis C.

Interferon therapy for HCV-associated glomerulonephritis: meta-analysis of controlled trials.

Interferon/pegylated interferon and ribavirin in HCV-associated kidney disease with or without cryoglobulinemia.

Lancet Countdown paper: what does it mean for nephrology?

Macrophage migration inhibitory factor (MIF) and thyroid hormone alterations in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

Mild cognitive impairment and kidney disease: clinical aspects

Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial

Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe

Nephrology and Public Policy Committee propositions to stimulate research collaboration in adults and children in Europe

Nephrology: achieving sustainability

Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges

Outcome and treatment of elderly patients with ANCA-associated vasculitis

Paving the way towards gender equality: how are we faring in nephrology?

Pegylated interferon and ribavirin in haemodialysis patients.

Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients.

Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients

Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis

Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.

Recommendations for the management of patients with immune-mediated kidney disease during the severe acute respiratory syndrome coronavirus 2 pandemic

Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis

Renal-limited vasculitis in children: a single-center retrospective long-term follow-up analysis

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis

Rituximab for minimal change disease in adults: long-term follow-up

Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?

Rituximab in relapsing or refractory ANCA-associated vasculitis: a case series of 16 patients

Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.

Serum Glutaredoxin Activity as a Marker of Oxidative Stress in Chronic Kidney Disease: A Pilot Study

Serum retinol-binding protein concentration and its association with components of the uremic metabolic syndrome in nondiabetic patients with chronic kidney disease stage 5.

The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council

The ERA-EDTA today and tomorrow: a progress document by the ERA-EDTA Council

The council for new therapies should immediately revoke their decision on eculizumab

The influence of hepatitis C and iron replacement therapy on plasma pentosidine levels in haemodialysis patients.

The nephrology crystal ball: the medium-term future

Treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia—anti-viral therapy vs rituximab

Whole blood cytokine attenuation by cholinergic agonists ex vivo and relationship to vagus nerve activity in rheumatoid arthritis.

[23 physicians comments on circumcision of small boys: The Swedish Medical Association should take a more humble approach].

[The council for new therapies position on eculizumab is unacceptable]